中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
22期
73-76
,共4页
奈达铂%多西他赛%非小细胞肺癌%临床疗效%安全性
奈達鉑%多西他賽%非小細胞肺癌%臨床療效%安全性
내체박%다서타새%비소세포폐암%림상료효%안전성
Nedaplatin%Docetaxel%Non small-cell lung cancer%Clinical efficacy%Safety
目的：探讨奈达铂联合多西他赛治疗非小细胞肺癌的临床效果,并评价其安全性。方法选取2011年5月~2014年1月在普宁市人民医院经CT和病理诊断证实为晚期非小细胞肺癌患者94例,将其随机分为观察组和对照组,每组47例。观察组采用奈达铂联合多西他赛治疗,对照组采用国产顺铂联合紫杉醇治疗。结果94例患者均可评价疗效,共完成320个周期,平均(3.4±0.4)个。与对照组相比,观察组患者CR例数较多,PD例数较少,有效率较高,差异有统计学意义(字2=3.859,P=0.049；字2=5.650,P=0.017；字2=4.609,P=0.032)。观察组恶心呕吐(40.43%)、白细胞减少(72.34%)、血小板减少(36.17%)、脱发(65.96%)、乏力(70.21%)、感觉异常(42.55%)等不良反应发生率较高。与对照组相比,观察组患者食欲不振发生率较低,白细胞减少发生率较高,差异有统计学意义(字2=7.892,P=0.005；字2=4.502,P=0.034)。结论奈达铂联合多西他赛治疗非小细胞肺癌临床效果较好,胃肠道反应较轻,但骨髓抑制较明显,总体上不良反应轻,患者容易耐受。
目的：探討奈達鉑聯閤多西他賽治療非小細胞肺癌的臨床效果,併評價其安全性。方法選取2011年5月~2014年1月在普寧市人民醫院經CT和病理診斷證實為晚期非小細胞肺癌患者94例,將其隨機分為觀察組和對照組,每組47例。觀察組採用奈達鉑聯閤多西他賽治療,對照組採用國產順鉑聯閤紫杉醇治療。結果94例患者均可評價療效,共完成320箇週期,平均(3.4±0.4)箇。與對照組相比,觀察組患者CR例數較多,PD例數較少,有效率較高,差異有統計學意義(字2=3.859,P=0.049；字2=5.650,P=0.017；字2=4.609,P=0.032)。觀察組噁心嘔吐(40.43%)、白細胞減少(72.34%)、血小闆減少(36.17%)、脫髮(65.96%)、乏力(70.21%)、感覺異常(42.55%)等不良反應髮生率較高。與對照組相比,觀察組患者食欲不振髮生率較低,白細胞減少髮生率較高,差異有統計學意義(字2=7.892,P=0.005；字2=4.502,P=0.034)。結論奈達鉑聯閤多西他賽治療非小細胞肺癌臨床效果較好,胃腸道反應較輕,但骨髓抑製較明顯,總體上不良反應輕,患者容易耐受。
목적：탐토내체박연합다서타새치료비소세포폐암적림상효과,병평개기안전성。방법선취2011년5월~2014년1월재보저시인민의원경CT화병리진단증실위만기비소세포폐암환자94례,장기수궤분위관찰조화대조조,매조47례。관찰조채용내체박연합다서타새치료,대조조채용국산순박연합자삼순치료。결과94례환자균가평개료효,공완성320개주기,평균(3.4±0.4)개。여대조조상비,관찰조환자CR례수교다,PD례수교소,유효솔교고,차이유통계학의의(자2=3.859,P=0.049；자2=5.650,P=0.017；자2=4.609,P=0.032)。관찰조악심구토(40.43%)、백세포감소(72.34%)、혈소판감소(36.17%)、탈발(65.96%)、핍력(70.21%)、감각이상(42.55%)등불량반응발생솔교고。여대조조상비,관찰조환자식욕불진발생솔교저,백세포감소발생솔교고,차이유통계학의의(자2=7.892,P=0.005；자2=4.502,P=0.034)。결론내체박연합다서타새치료비소세포폐암림상효과교호,위장도반응교경,단골수억제교명현,총체상불량반응경,환자용역내수。
Objective To explore clinical efficacy of Nedaplatin combined with Docetaxel for non small-cell lung can-cer and evaluation of safety. Methods 94 patients with advanced non small-cell lung cancer which were confirmed by CT and pathological diagnosis from May 2011 to January 2014 of Puning People's Hospital were randomly divided into the observation group and the control group and every group had 47 patients. Patients in the observation group were treated by Nedaplatin combined with Docetaxel, while patients in the control group were treated by homemade Cis-platinum combined with Paclitaxel. Results 94 patients were evaluated clinical efficacy and they completed 320 cycles and mean cycles were (3.4±0.4). Compared with the control group, the observation group had more CR patients, less PD patients and higher effective percentage. The differences were statistically significant (χ2=3.859, P=0.049;χ2=5.650, P=0.017;χ2=4.609, P=0.032). Incidence of nausea and vomiting (40.43%), aleucocytosis (72.34%), lipsotrichia (36.17%), fatigue (65.96%), weak (70.21%), abnormal sensation (42.55%) were high in the observation group. Compared with the control group, incidence of anorexia were lower while incidence of aleucocytosis were higher, the differences were sta-tistically significant (χ2=7.892, P=0.005;χ2=4.502, P=0.034). Conclusion The clinical efficacy of Nedaplatin com-bined with Docetaxel for non small-cell lung cancer is better and the gastrointestinal reaction is light, but bone marrow suppression is obvious. The overall adverse reaction is light and patients are easy to tolerate.
